By analyzing a patient’s DNA we are able to search for specific genetic variants that put one at an increased risk of Hereditary Cancer.
BPH uses the latest advances in Next Generation Sequencing (NGS) to analyze a patient’s sample. Thus, providing comprehensive reports of genetic variants and risk factors. The ordering physician, supported by our genetic counselors, is able to formulate a treatment protocol to address any negative findings. Awareness of one’s risk factors allows patients and their physicians to take a proactive, rather than reactive approach to managing identified risks.
BPH is a strong supporter of the American Society of Clinical Oncologists (ASCO)*, particularly with regard to their recommendations on genetic and genomic testing elaborated in the 2009 policy statement: follow-up care; increased education and awareness; multidisciplinary research; pre- and post-test counseling; informed consent; accessibility through insurance; privacy and data security; and, continued oversight for accuracy, validity and quality of genetic test and testing laboratories.
[American Society of Clinical Oncologists Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility, 2009. ].
Who is at risk?
Get the most affordable prescriptions focused on you.